Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial.

ABSTRACT:

Context

Acute ST-segment elevation myocardial infarction (STEMI) is a leading cause of morbidity and mortality. In experimental models of MI, erythropoietin reduces infarct size and improves left ventricular (LV) function.

Objective

To evaluate the safety and efficacy of a single intravenous bolus of epoetin alfa in patients with STEMI.

Design, setting, and patients

A prospective, randomized, double-blind, placebo-controlled trial with a dose-escalation safety phase and a single dose (60,000 U of epoetin alfa) efficacy phase; the Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction (REVEAL) trial was conducted at 28 US sites between October 2006 and February 2010, and included 222 patients with STEMI who under

SUBMITTER: Najjar SS 

PROVIDER: S-EPMC3486644 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature